Term Name: baricitinib
Synonyms: 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile, 2-(3-(4-(3H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile, baricitinib, baricitinibum, INCB 028050, INCB-028050, INCB028050, LY 3009104, LY-3009104, LY3009104, Olumiant, {1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile
Definition: A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidine substituted by a 1-[3-(cyanomethyl)-1-(ethanesulfonyl)azetidin-3-yl]-1H-pyrazol-4-yl group at position 5. It is an FDA approved selective Janus Kinase 1 and 2 (JAK1 and JAK2) inhibitor used for the treatment of rheumatoid arthritis.
Ontology: ChEBI [CHEBI:95341]  ( EBI )

Relationships
is a type of: azetidines nitrile pyrazoles pyrrolopyrimidine sulfonamide
has_role: anti-inflammatory agent antirheumatic drug antiviral agent EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor immunosuppressive agent